A network-driven computational framework for identifying FDA-approved drug repurposing across heterogeneous brain cancers

The proposed profile-network-based method achieved 70%-95% accuracy for drug repurposing across different disease categories related to the brain. <i>In-mac</i> and ReBrain were used for the repurposing of known drugs for the treatment of brain cancer. As a result, three repurposed drugs were identified as priorities: (i) mefloquine (reference drug: vorasidenib citrate), (ii) clofibric acid (reference drug: carmustine), and armillarisin A (reference drug: lomustine). These results also suggest repurposing candidates for synergistic combinations across different brain tumors. The two applications developed in this work are freely accessible and in the public domain at https://assay.smallmoles.com/escorwin.